Dec 12 (Reuters) – GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader use.
The British drugmaker said a formal and final approval to market the vaccine for this expanded indication in the European Union was expected in February next year, with the vaccine competing against Pfizer’s Abrysvo and Moderna’s mResvia.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Subhranshu Sahu)
Comments